Letter by rosenstein and parra regarding article, "greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in myocardial infarction 38"

Robert S. Rosenstein, David Parra

Research output: Contribution to journalLetterpeer-review

Fingerprint

Dive into the research topics of 'Letter by rosenstein and parra regarding article, "greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: Thrombolysis in myocardial infarction 38"'. Together they form a unique fingerprint.